** Shares of Clarity Pharmaceuticals CU6.AX up ~2% at A$4.135, set for a fourth consecutive session of gain
** Radiopharma co says the U.S. Food and Drug Administration has granted Fast Track Designation for its prostate cancer drug, 64Cu-SAR-bisPSMA
** Says the drug has several advantages over currently approved ones, including improved diagnostic performance and flexible imaging schedule, among others
** Stock rises as much as 15.5% earlier in the day, marking its biggest intraday pct gain since Dec. 18, 2024
** About 2 mln shares change hands, 1.1x the 30-avg
** Stock more than doubled in value last year
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。